Abstract
Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Current Drug Safety
Title: Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Volume: 6 Issue: 2
Author(s): Peter Vestergaard and Susanna vid Streym Thomsen
Affiliation:
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Abstract: Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Export Options
About this article
Cite this article as:
Vestergaard Peter and vid Streym Thomsen Susanna, Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism, Current Drug Safety 2011; 6 (2) . https://dx.doi.org/10.2174/157488611795684703
DOI https://dx.doi.org/10.2174/157488611795684703 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Gene Therapy: Optimising DNA Delivery to the Nucleus
Current Drug Targets Milk Thistle: A Future Potential Anti-Osteoporotic and Fracture Healing Agent
Current Drug Targets Vitamin D Metabolites and/or Analogs: Which D for Which Patient?
Current Vascular Pharmacology Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety Role of Vitamin D in the Pathophysiology and Treatment of Type 2 Diabetes
Current Diabetes Reviews The Role of Parathyroid Hormone-Related Protein (PTHrP) in the Pathophysiology of Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine Recent Applications of Doebner, Doebner-von Miller and Knoevenagel-Doebner Reactions in Organic Syntheses
Current Organic Synthesis Osteopontin: An Effector and an Effect of Tumor Metastasis
Current Molecular Medicine Cell Cycle as a Target of Antineoplastic Drugs
Current Pharmaceutical Design Interaction of Chemokines with their Receptors - From Initial Chemokine Binding to Receptor Activating Steps
Current Medicinal Chemistry The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy Vitamin D and the Metabolic Syndrome
Current Vascular Pharmacology Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Stem Cell and Regenerative Medicine
Current Stem Cell Research & Therapy Vitamin D Supplementation: A Promising Approach for the Prevention and Treatment of Strokes
Current Drug Targets Evaluation of Osteoporosis Risk Associated with Chronic Use of Morphine, Fentanyl and Tramadol in Adult Female Rats
Current Drug Safety Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry